✨ Free AI Report
Biomea Fusion, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Biomea Fusion, Inc.
Company Research

Biomea Fusion, Inc.: Business Overview, Financials & Competitive Analysis

Biomea Fusion, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Pre-revenue metabolic disease biotech with promising early-stage diabetes program and improving burn rate, but facing execution risk and clinical trial success dependency. Biomea reported a net loss of $12.4 million in Q1 2026, down from $29.3 million in Q1 2025, showing improved operational discipline. However, the company remains pre-revenue.

What is Biomea Fusion, Inc.'s industry? Biomea Fusion, Inc. (biomeafusion.com) operates in Pharmaceuticals. AskCyborg classifies Biomea Fusion, Inc. under Pharmaceuticals in its company registry.

Biomea Fusion is a clinical-stage biotechnology company specializing in oral small-molecule therapies targeting metabolic diseases such as diabetes and obesity. The company's lead candidate, icovamenib, is in clinical...

4/ 10Mixed

Cyborg Score thesis

Pre-revenue metabolic disease biotech with promising early-stage diabetes program and improving burn rate, but facing execution...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Biomea Fusion, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Biomea Fusion, Inc.

AskCyborg analysts argue the bull and bear cases for Biomea Fusion, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Biomea Fusion, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Biomea Fusion, Inc. Overview

Pro stress-test →

Biomea Fusion is a clinical-stage biotechnology company specializing in oral small-molecule therapies targeting metabolic diseases such as diabetes and obesity. The company's lead candidate, icovamenib, is in clinical and preclinical evaluation for type 1 and type 2 diabetes, while BMF-650 is being developed as a next-generation oral GLP-1 receptor agonist for obesity.

Strategic Profile

Pro stress-test →

As a clinical-stage entity without approved products or product revenue, Biomea Fusion relies on equity financings to fund research and development. The company has demonstrated disciplined cash management through sharp reductions in operating expenses as part of its restructuring efforts.

Competitive Landscape

Pro stress-test →

Biomea Fusion competes in the oral small-molecule diabetes and obesity therapeutics space against larger biopharmaceutical companies and other clinical-stage competitors focused on metabolic disease. Its oral formulation approach and focus on beta-cell restoration differentiate it from injectable GLP-1 agonists currently dominating obesity treatment.

Industry Context

Biomea Fusion, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2017 · Headquarters: San Carlos, California, US · Revenue: $0 (clinical-stage, no approved products) · Market cap: $123 million

What the analysts stress-tested

The top findings that survived the multi-agent debate for Biomea Fusion, Inc..

  • In Q1 2026, Biomea beat analyst consensus on EPS ($-0.17 vs. $-0.24 expected), driven by significant operating expense reduction. This demonstrates management's ability to preserve cash runway during a clinical development phase.
  • Icovamenib showed a 52% increase in mean C-peptide AUC at Week 12 in recently-diagnosed type 1 diabetes patients (April 2026), with persistence observed through Week 52. This durability signal strengthens the beta-cell recovery narrative.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026Positive 52-week results from COVALENT-112 Phase II trial showing C-peptide improvement and durability in type 1 diabetes
  • August 2026Completion of enrollment in COVALENT-211 Phase II trial of icovamenib in insulin-deficient type 2 diabetes
  • +1 moreTrack every material event for Biomea Fusion, Inc. as it happens. Explore monitoring →
Get alerted when Biomea Fusion, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Novo NordiskGLP-1 receptor agonists for diabetes and obesity→Eli LillyGLP-1 and tirzepatide therapies for diabetes and obesity→Viking TherapeuticsOral dual GLP-1/GCG agonist for diabetes and obesity→Structure TherapeuticsOral GLP-1 receptor agonist in development→

Compare Biomea Fusion, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Biomea Fusion, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Biomea Fusion, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Biomea Fusion, Inc. and its top competitor on Cyborg Score”
“What did Biomea Fusion, Inc. do this quarter?”
“Is Biomea Fusion, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Biomea Fusion, Inc. do?+
Biomea Fusion is a clinical-stage biotechnology company specializing in oral small-molecule therapies targeting metabolic diseases such as diabetes and obesity. The company's lead candidate, icovamenib, is in clinical...
What is Biomea Fusion, Inc.'s Cyborg Score?+
Biomea Fusion, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Biomea Fusion, Inc.'s main competitors?+
Named competitors include Novo Nordisk, Eli Lilly, Viking Therapeutics, Structure Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Biomea Fusion, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Biomea Fusion, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Biomea Fusion, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.